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match in related transplant is unlikely. In contrast, investigating
the frequency of a donor-recipient HFE mismatch in a series of 60
unrelated bone marrow transplants otherwise perfectly matched on
the HLA-A,B,C,DRB1,DQB1 loci, we found a mismatch in 10
cases. These data suggest that HFE could be a potent histocom-
patibility antigen in humans in view of its structural polymorphism.
129
MULTIDISCIPLINARY APPROACH TO DEVELOPMENT OF A GVHD OUT-
PATIENT CLINIC
Yount, P.1, Vance, E.A.1, Agura, E.D.1, Berryman, R.B.1, Fay, J.W.1,
Pineiro, L.1, Bengtson, E.1, Bair, J.D.2 1. Baylor Sammons Cancer
Center and Texas Oncology, P.A., Dallas, TX; 2. Baylor University
Medical Center, Dallas, TX.
Managing GVHD is a particularly challenging aspect of the care
of blood and marrow transplant recipients. In the Blood and
Marrow Transplant program at Baylor University Medical Center,
the GVHD patients were identiﬁed as a population that could
beneﬁt from an interdisciplinary approach in a specialized clinic
setting. A questionnaire was sent to the transplant physician group
to gauge interest in and the need for this clinic. It was determined
that enough interest was present and a patient population would
support the organization of this program. The interdisciplinary
team consisted of an oncologist as team leader, dermatologist,
clinic manager, contract administrator, nurse manager, pharmacist,
biostatistician, physical therapist, occupational therapist, dietitian,
enterostomal therapist, social worker, and chaplain. The team
gathered for regular meetings to decide on structure, services, and
supplies that would be needed to support such an endeavor. The
clinic manager and contract administrator investigated ﬁnancial
reimbursement for each discipline in the outpatient setting. Orga-
nization of the GVHD clinic recommended that each patient see
the medical team leader followed by other specialty areas that
would beneﬁt the patient. A key component for a successful clinic
is data collection for patients before their appointments to assist
clinicians with a thorough needs assessment. Each discipline of-
fered a data collection tool and these were compiled by a team
member. This tool includes sections on medication, medical symp-
toms, skin assessment, nutrition, physical and occupational ther-
apy, and psychosocial needs. Prior to patient’s appointments, ques-
tionnaires are mailed with the instructions to complete and bring
to their appointment. Research protocols for disciplines in this
clinic are being developed. Taking a multidisciplinary approach to
a GVHD clinic is a key factor in developing a successful program.
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IL-7 IS NECESSARY FOR THE DEVELOPMENT OF EXPERIMENTAL
GRAFT-VERSUS-HOST DISEASE (GVHD)
Chung, B., Dudl, E.P., Toyama, A., Barsky, L., Price, M., Weinberg,
K.I. Childrens Hospital Los Angeles, Los Angeles, CA.
Interleukin 7 (IL-7) promotes both thymopoiesis and the survival
and proliferation of mature T lymphocytes. Although IL-7 en-
hances immune reconstitution following hematopoietic stem cell
transplantation (HSCT), its effect on mature T lymphocytes in
allogeneic bone marrow transplantation (BMT) could lead to ex-
acerbation of GVHD. However, recent experiments to determine
whether IL-7 treatment worsens GVHD have produced conﬂict-
ing results. Therefore, this study was designed to examine whether
IL-7 is necessary for the induction of GVHD by maintaining
donor mature T cells following allogeneic BMT. In order to
induce GVHD, B6 or B6/IL-7
/
 (CD45.2 H2Kb) recipient
mice were lethally irradiated (1300 cGy) and co-transplanted with
4x106 lymph node (LN) and 1x106 T cell depleted (TCD) BM cells
from either congenic B6.SJL (CD45.1, H2Kb) or major MHC
mismatched allogeneic Balb/C (CD45.2, H2Kd) donor mice. Fol-
lowing transplantation, the recipient mice received either human
recombinant IL-7 (rhIL-7) 500ng BID or PBS from day 1 to 60.
The survival rate was similar in all groups of mice for the ﬁrst 25
days after transplantation and no evidence of GVHD was detected
from allogeneically transplanted B6/IL-7
/
 recipients treated
with PBS. In contrast, GVHD-related mortality and morbidity in
allogeneic recipients treated with IL-7 were increased compared to
the PBS treated groups. IL-7 treatment signiﬁcantly reduced sur-
vival in the B6/IL-7
/
 mice (15%, n  20) compared to the PBS
treated B6/IL-7
/
 recipients (59%, n 17 [p 0.005]). Further-
more, the overall GVHD clinical index of IL-7 treated B6/IL-7
/

was signiﬁcantly lower than the PBS treated B6/IL-7
/
 recipients
(p  0.05). The recovery of donor CD4 or CD8 T cells in the
periphery of the PBS treated B6/IL-7
/
 recipients was signiﬁ-
cantly lower than the IL-7 treated B6/IL-7
/
 mice by day 30
post-transplantation. In addition, IL-7 treatment increased the
number of activated (CD69 positive) donor-derived CFSE labeled
CD4 and CD8 LN T lymphocytes in the lymph nodes of B6/IL-
7
/
 mice compared to PBS treated B6/IL-7
/
 recipients indi-
cating that IL-7 enhances maintenance of dividing activated al-
logneic mature T cells. Therefore, it is likely that IL-7 is necessary
for the development of GVHD presumably by maintaining the
adequate number of activated donor T cells in the periphery of the
recipient animals post-allogeneic BMT.
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THE ABSENCE OF PEYER’S PATCHES OR HOST TNF- DOES NOT
AFFECT GVHD PROGRESSION IN AN ALLOGENEIC BMT MODEL USING
EXTENSIVE CONDITIONING REGIMENS
Welniak, L.A.1, Kuprash, D.V.2, Tumanov, A.V.2, Sun, K.1, Stull,
S.W.2, Anver, M.R.2, Nedospasov, S.A.2, Murphy, W.J.1 1. University
of Nevada, Reno, Reno, NV; 2. SAIC-Frederick, Frederick, MD.
Peyer’s patches (PP) have been previously shown to play a critical
role in the initiation of acute lethal GVHD in a non-irradiated
murine model (Murai et al., 2003). This report utilized IL-7
receptor antibody treatment of pregnant mice to inhibit the devel-
opment of PPs in the fetus. We wanted to assess GVHD progres-
sion in mice congenitally deﬁcient in PP presence and function.
The absence of various members of the TNF and TNF-R families
also affects secondary lymphoid structure and organization. The
presence of PP has varied between different independently gener-
ated TNF knockout strains which may be related to the close
linkages of tnf with lta and ltb genes. A new TNF deﬁcient strain
has been developed that lacks PPs, displays the defects character-
istic of TNF ablation but not the LT associated defects character-
ized by lack of lymph nodes and defects in splenic microarchitec-
ture. To examine the role of host-derived TNF family members in
acute lethal GVHD, we also had to assess the role of secondary
lymphoid structures. We utilized a full MHC mismatched mode of
BALB/c (H2d) cells into myeloablated C57BL/6 (H2b) recipients.
We lethally irradiated wild type (WT) mice, TNF- deﬁcient mice
with Peyer’s patches (PP) and TNF- deﬁcient mice without
Peyer’s patches (PP-) followed by infusion of allogeneic bone
marrow and spleen cells. We observed no difference in the survival
of the three groups of mice (median day of death ranged from 26
to 27). In addition, no signiﬁcant differences were observed in
GVHD associated histopathological lesions in the small intestine.
Hisopathological lesions observed in the colon were similar in both
the PP and PP- TNF- deﬁcient recipients. Based on our ob-
servations, we conclude that (1) Peyer’s patches and (2) host
TNF- are not required for the development of acute lethal
GVHD in mice that received extensive conditioning and allogeneic
bone marrow transplantation.
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DEVELOPMENT OF NUTRITION ALGORITHMS FOR CHRONIC GVHD
Bair, J.D.1, Roberts, S.R.1, Thompson, J.1, Agura, E.D.2, Berryman,
R.B.2, Fay, J.W.2, Pineiro, L.2, Vance, E.A.2 1. Baylor University
Medical Center, Dallas, TX; 2. Baylor Sammons Cancer Center and
Texas Oncology, P.A., Dallas, TX.
One of the challenges for patients with chronic GVHD is to
maximize quality of life by maintaining optimal nutritional intake
and minimizing loss of lean body mass. Registered Dietitians
(RD’s) play an integral role in the nutritional care of patients in the
Blood and Marrow Transplant program at Baylor University Med-
ical Center and are part of the team establishing a new GVHD
clinic. Patients referred to the GVHD clinic are seen by the RD
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